November 29, 2024 Holiday Shopping Sets New Records With $6.1B Spent Online
November 25, 2024 Bitcoin Nears $100K: Crypto Revolution Reshapes Wall Street
November 18, 2024 Biden’s Missile Strategy: Escalation Or Path To Peace?
November 10, 2024 Wall Street Soars: Trump’s Victory Ignites Market Surge
Nvidia’s Pullback: The Calm Before Takeoff
Tesla Faces An Uphill Battle In 2025
Amazon: A Compelling Buying Opportunity
Xiaomi: Anatomy Of A Tesla Killer
October 22, 2024 A Comprehensive Guide to RoadRunner Auto Transport Services
October 3, 2024 Mastering Trading Indicators: Your Essential Toolkit For Success
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
April 12, 2024 Improve Your Financial Status: A How-To Guide
Danaher (DHR) Stock Forecast for 2024, 2025, 2026. Sell or Buy?
Updated: December 5, 2024 (12:08)
Sector: HealthcareThe share price of Danaher Corp. (DHR) now
News Impact Analyzer
Full report|
This Week
|
Na | Impact: Na | News: Na |
|
Previous Week
|
Na | Impact: Na | News: Na |
|
Two Weeks Ago
|
Bullish | Impact: 5 | News: 3 (1/2/0) |
|
Three Weeks Ago
|
Na | Impact: Na | News: Na |
Analysts predictions
Full report|
This Week
|
Neutral | Opinions: Na |
|
Previous Week
|
Neutral | Opinions: Na |
|
Two Weeks Ago
|
Neutral | Opinions: Na |
|
Three Weeks Ago
|
Neutral | Opinions: Na |
Analyzing the Most Important DHR news
Optimism for Life Science Stocks Amid Tariff Concerns
Minimal Short Interest: DHR Among S&P 500's Fortified Stocks
DiamondRock Boosts Portfolio with $30M Acquisition of AC Hotel Minneapolis
Historical and forecast chart of Danaher stock
The chart below shows the historical price of Danaher stock and a prediction chart for the next month.
For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast,
and Weighted Average Best Forecast. Detailed values for the Danaher stock price can be found in the table below.
Long-term forecasts by years.
Danaher Corp. Analysts predictions review
As of now, Panda has combed through 0 analytical articles which are directly related to DHR from the last 30 days. Out of these, 0 clearly showcase a bullish trend, while 0 see a bearish trend as the more likely scenario, and 0 stay neutral.
To identify the dominant trend, we took into account analytical articles from the past 30 days, spanning from Jan 01, 1970 to Jan 01, 1970.
Danaher's Conservative Caution: Navigating Growth Uncertainty
In this review of From Growth to Value's analytical financial article, we explore the author's nuanced perspective on DHR stock, marked by a Neutral stance. With 361 publications since 2016, the author has demonstrated consistent engagement with the financial community, averaging an impressive frequency of work. Boasting over 33,000 subscribers, the author's viewpoints resonate broadly, highlighting a significant following. The metrics further underscore the author’s credibility, indicating an excellent level of authority that assures well-founded, reliable opinions in the realm of financial analysis. As you delve into this review, anticipate an insightful, balanced examination rooted in the author’s well-regarded expertise and neutral positioning on the DHR stock.
Key Theses of the Review
- Danaher reported acceptable Q3 earnings with a noted cautious stance by management.
- The company's management has shown a tendency to be conservative and avoid revising guidance despite continued earnings beats.
- Danaher has experienced its first growth quarter since September 2022, but the company's reluctance to update guidance persists.
- The company is still undergoing a bioprocessing downcycle, but positive momentum is noted.
- Buyback programs and significant cash flow generation could lead to further stock repurchases.
Factors Influencing Danaher's Stock Price
Conservative Guidance
The reluctance to revise guidance despite revenue and earnings beats may create investor unease and pressure stock prices in the short term, as it indicates uncertainty about future growth rates.
Bioprocessing Downcycle
The continuation of the bioprocessing downcycle affects Danaher's growth despite improvements, impacting investor sentiment and maintaining pressure on the company's stock price.
Positive Earnings Streak
Danaher's 16th consecutive quarter beating top and bottom-line estimates boosts investor confidence, albeit marginally due to unchanging conservative guidance.
Cash Flow and Buyback Potential
Future buyback plans with significant ongoing cash flow generation may support the stock price by increasing EPS if growth resumes in the forecast periods.
China's Gradual Recovery
A more gradual than expected recovery in China creates uncertainty about overall growth prospects, slightly weakening investor confidence.
Review the original Analysis
Danaher: Heading for Bright Horizons in Molecular Testing and Bioprocessing
Hunter Wolf Research delivers an incisive analytical review with a firm bullish stance on DHR stock, emphasizing the promising potential that lies ahead. As a seasoned contributor since 2015, the author is known for a prolific output, boasting 123 publications over an eight-year period. This impressive ratio speaks to their dedication and expertise in the financial domain. Further underscoring the author's influence, they have garnered a loyal following of 1,696 subscribers, reflecting a significant reach among financial enthusiasts and professionals. The author's viewpoints are highly credible, positioning them as a trusted voice in the industry. This combination of authority, frequency, and audience engagement makes Hunter Wolf Research's analysis of DHR stock both authoritative and compelling, encouraging investors to closely consider the optimistic insights presented.
Key Theses of the Article
- Danaher is expected to continue its recovery in bioprocessing and gain market share in molecular testing.
- Cepheid's market share gains and FDA authorization for its Hepatitis C RNA test position Danaher for further growth.
- Despite challenges in China, Danaher is projected to outpace market growth through molecular testing, mergers & acquisitions, and margin expansion.
- A strong position in the single-use bioprocessing market is expected to contribute to Danaher's growth.
Factors Influencing DHR Stock Price
Recovery in Bioprocessing Market
The recovery in the bioprocessing sector is essential due to high-single-digit growth in orders and stabilization in China, potentially boosting Danaher's performance. This recovery reveals broader sector resilience, directly impacting Danaher's financial health and stock performance.
Cepheid's Market Share Gains in Molecular Testing
Cepheid's advances in molecular testing, including FDA approval for its Hepatitis C RNA test, signify major growth potential, reflecting Danaher's capacity for innovation. These advances are likely to spur revenue growth, significantly impacting the company's stock valuation.
Outlook for China Operations
China's stabilization in the bioprocessing sector is positive, but uncertainty remains with high teens decline in Q2. Given China's contribution to over 10% of revenue, this uncertainty tenuously affects the stock price outlook.
Improvement in Life Science Capital Funding
Stronger life sciences funding could lead to a higher demand for Danaher products, notably as interest rates decrease. While peripheral, improved funding supports steady demand and gradual positive shifts in stock valuation.
Single-Use Bioprocessing Market Growth
Danaher's strong stance in the growing single-use bioprocessing sector, predicted to grow at 18.4% CAGR, offers a promising market expansion avenue. This robust growth expectation aligns with revenue goals, likely bolstering stock values.
Review the original Analysis
Commentary
Danaher is making waves in the bioprocessing and molecular testing markets, showcasing a strong narrative for growth. Driving this upward trajectory are Cepheid's impressive gains in market share and the recent FDA nod for the Hepatitis C RNA test — powerful indicators of the company’s innovation capabilities. Such advancements herald revenue growth, casting a favorable light on Danaher’s stock potential.
Moreover, the recovery in the bioprocessing sector, even amidst challenges in China, and Danaher's deep-rooted presence in the thriving single-use bioprocessing market, signals resilience and strategic foresight. Taking into account these factors and their influences, the stock is set expected to hold a positively strong momentum in the next 15 days and the month ahead. Investors might find the current environment enticing for capitalizing on these strategic growth avenues.
Comprehensive Analysis of Danaher (DHR) Stock Market Performance
Our multifaceted analysis of Danaher's stock market is grounded in the company's key news stories, insights from reputable analysts, as well as mathematical and technical evaluations. Taking into account assessments from each of these aspects in real-time helps us address the most crucial questions for investors in the most objective way possible:
- When should I take profit in Danaher stock?
- When should I record a loss on Danaher stock?
- What are analysts' forecasts for Danaher stock?
- What is the future of Danaher stock?
We forecast Danaher stock performance using neural networks based on historical data on Danaher stocks.
Danaher Corp. News influencing stock rates
As of now, Panda has combed through 3 news items directly related to DHR from the last 30 days. Out of these, 1 clearly showcase a bullish trend, while 0 display bearish tendencies, and 2 events are neutral.
Based on an analysis of the most important news from the last 30 days affecting DHR shares, it's clear that bullish sentiments are completely overshadowing bearish ones. The impact of positive news is more than five times as dominant as that of negative developments.
The news analyzed fell within the period from Nov 15, 2024, to Nov 15, 2024.
Wolfe Boosts Danaher: Sees Upside After Recent Drop
Danaher Tops Q3 Expectations with Diverse Growth, Boosts Investor Confidence
Danaher Outperforms Expectations with Strong Q3 Figures; Confirms Positive Outlook
Danaher Surpasses Q3 Expectations with Non-GAAP EPS Boost
Danaher Q3 Earnings: Lower Estimates Loom Large
Telesis Bio Joins Forces with Beckman Coulter to Innovate DNA & mRNA Solutions
Danaher Maintains $0.27 Quarterly Dividend Payout
Fortive's Strategic Shift: Testing Unit Spin-off Confirmed
Danaher Corporation develops, manufactures and markets professional, medical, industrial and commercial products and services. The company operates in three segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of the body, including genes, proteins, metabolites and cells, in order to understand the causes of diseases, identify new therapies and test new drugs remedies and vaccines; Diagnostic business, which offers analytical instruments, reagents, consumables, software and services; and Environmental and Application Solutions, which include a variety of activities, including water quality assessment and product identification. Danaher has facilities for research and development, manufacturing, sales, distribution, service and administrative centers in more than 60 countries.
Danaher daily forecast for a month
| Date | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Dec 07 | 237.02 | 235.62 | 237.68 | 0.88 |
| Dec 08 | 236.71 | 235.95 | 238.20 | 0.95 |
| Dec 09 | 237.47 | 236.73 | 238.80 | 0.87 |
| Dec 10 | 235.09 | 234.01 | 235.80 | 0.76 |
| Dec 11 | 236.36 | 235.68 | 237.24 | 0.66 |
| Dec 12 | 236.27 | 235.44 | 236.83 | 0.59 |
| Dec 13 | 237.33 | 235.64 | 238.83 | 1.35 |
| Dec 14 | 237.31 | 235.72 | 238.85 | 1.33 |
| Dec 15 | 239.44 | 238.60 | 240.18 | 0.66 |
| Dec 16 | 238.70 | 236.98 | 239.89 | 1.23 |
| Dec 17 | 237.60 | 235.96 | 238.91 | 1.25 |
| Dec 18 | 236.53 | 235.26 | 237.93 | 1.14 |
| Dec 19 | 236.86 | 235.92 | 238.71 | 1.18 |
| Dec 20 | 237.98 | 237.33 | 238.95 | 0.68 |
| Dec 21 | 236.83 | 235.58 | 237.90 | 0.99 |
| Dec 22 | 238.68 | 238.09 | 240.30 | 0.93 |
| Dec 23 | 239.90 | 239.01 | 241.53 | 1.05 |
| Dec 24 | 240.38 | 239.51 | 240.86 | 0.56 |
| Dec 25 | 240.11 | 238.51 | 240.67 | 0.91 |
| Dec 26 | 237.76 | 236.95 | 239.12 | 0.91 |
| Dec 27 | 238.55 | 236.71 | 239.24 | 1.07 |
| Dec 28 | 237.26 | 235.38 | 238.59 | 1.36 |
| Dec 29 | 236.47 | 236.00 | 237.99 | 0.84 |
| Dec 30 | 238.01 | 236.39 | 238.92 | 1.07 |
| Dec 31 | 237.18 | 235.45 | 238.13 | 1.14 |
| Jan 01 | 236.47 | 234.72 | 237.86 | 1.34 |
| Jan 02 | 236.94 | 235.16 | 238.50 | 1.42 |
| Jan 03 | 236.61 | 235.78 | 238.45 | 1.13 |
| Jan 04 | 237.08 | 235.28 | 237.58 | 0.98 |
| Jan 05 | 234.76 | 234.05 | 235.63 | 0.67 |
Danaher Daily Price Targets
Danaher Stock Forecast 12-07-2024.
Forecast target price for 12-07-2024: $237.02.
Positive dynamics for Danaher shares will prevail with possible volatility of 0.868%.
Pessimistic target level: 235.62
Optimistic target level: 237.68
Danaher Stock Forecast 12-08-2024.
Forecast target price for 12-08-2024: $236.71.
Negative dynamics for Danaher shares will prevail with possible volatility of 0.944%.
Pessimistic target level: 235.95
Optimistic target level: 238.20
Danaher Stock Forecast 12-09-2024.
Forecast target price for 12-09-2024: $237.47.
Positive dynamics for Danaher shares will prevail with possible volatility of 0.865%.
Pessimistic target level: 236.73
Optimistic target level: 238.80
Danaher Stock Forecast 12-10-2024.
Forecast target price for 12-10-2024: $235.09.
Negative dynamics for Danaher shares will prevail with possible volatility of 0.758%.
Pessimistic target level: 234.01
Optimistic target level: 235.80
Danaher Stock Forecast 12-11-2024.
Forecast target price for 12-11-2024: $236.36.
Positive dynamics for Danaher shares will prevail with possible volatility of 0.658%.
Pessimistic target level: 235.68
Optimistic target level: 237.24
Danaher Stock Forecast 12-12-2024.
Forecast target price for 12-12-2024: $236.27.
Negative dynamics for Danaher shares will prevail with possible volatility of 0.589%.
Pessimistic target level: 235.44
Optimistic target level: 236.83
DHR (DHR) Monthly Stock Prediction for 2025
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan. | 243.32 | 231.57 | 253.20 | 8.54 |
| Feb. | 250.47 | 245.04 | 255.73 | 4.18 |
| Mar. | 246.96 | 242.12 | 257.34 | 5.91 |
| Apr. | 240.05 | 234.67 | 245.09 | 4.25 |
| May. | 236.35 | 224.94 | 245.62 | 8.42 |
| Jun. | 230.23 | 222.17 | 240.87 | 7.76 |
| Jul. | 222.17 | 212.06 | 227.46 | 6.77 |
| Aug. | 229.33 | 221.62 | 241.21 | 8.12 |
| Sep. | 235.43 | 225.21 | 245.48 | 8.26 |
| Oct. | 228.51 | 224.35 | 237.46 | 5.52 |
| Nov. | 220.51 | 208.31 | 228.07 | 8.66 |
| Dec. | 215.72 | 212.40 | 226.14 | 6.08 |
Danaher forecast for this year
Danaher Stock Prediction for Jan 2025
An uptrend is forecast for this month with an optimal target price of $243.317. Pessimistic: $231.57. Optimistic: $253.20
Danaher Stock Prediction for Feb 2025
An uptrend is forecast for this month with an optimal target price of $250.47. Pessimistic: $245.04. Optimistic: $255.73
Danaher Stock Prediction for Mar 2025
An downtrend is forecast for this month with an optimal target price of $246.964. Pessimistic: $242.12. Optimistic: $257.34
Danaher Stock Prediction for Apr 2025
An downtrend is forecast for this month with an optimal target price of $240.049. Pessimistic: $234.67. Optimistic: $245.09
Danaher Stock Prediction for May 2025
An downtrend is forecast for this month with an optimal target price of $236.352. Pessimistic: $224.94. Optimistic: $245.62
Danaher Stock Prediction for Jun 2025
An downtrend is forecast for this month with an optimal target price of $230.231. Pessimistic: $222.17. Optimistic: $240.87
Danaher Stock Prediction for Jul 2025
An downtrend is forecast for this month with an optimal target price of $222.172. Pessimistic: $212.06. Optimistic: $227.46
Danaher Stock Prediction for Aug 2025
An uptrend is forecast for this month with an optimal target price of $229.326. Pessimistic: $221.62. Optimistic: $241.21
Danaher Stock Prediction for Sep 2025
An uptrend is forecast for this month with an optimal target price of $235.426. Pessimistic: $225.21. Optimistic: $245.48
Danaher Stock Prediction for Oct 2025
An downtrend is forecast for this month with an optimal target price of $228.505. Pessimistic: $224.35. Optimistic: $237.46
Danaher Stock Prediction for Nov 2025
An downtrend is forecast for this month with an optimal target price of $220.507. Pessimistic: $208.31. Optimistic: $228.07
Danaher Stock Prediction for Dec 2025
An downtrend is forecast for this month with an optimal target price of $215.722. Pessimistic: $212.40. Optimistic: $226.14
Danaher (DHR) Monthly Stock Prediction for 2026
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 227.50 | 216.04 | 238.97 | 9.60 |
| Feb | 228.93 | 217.08 | 235.18 | 7.70 |
| Mar | 238.23 | 234.23 | 245.23 | 4.49 |
| Apr | 240.73 | 231.29 | 247.98 | 6.73 |
| May | 235.68 | 225.45 | 247.55 | 8.93 |
| Jun | 249.37 | 236.97 | 259.67 | 8.74 |
| Jul | 264.38 | 259.20 | 274.19 | 5.47 |
| Aug | 261.42 | 251.72 | 275.33 | 8.57 |
| Sep | 248.61 | 240.26 | 252.96 | 5.02 |
| Oct | 252.96 | 240.03 | 266.77 | 10.02 |
| Nov | 238.44 | 230.09 | 249.29 | 7.70 |
| Dec | 245.12 | 234.14 | 251.64 | 6.95 |
Danaher (DHR) Monthly Stock Prediction for 2027
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 247.69 | 242.14 | 260.35 | 6.99 |
| Feb | 248.90 | 240.54 | 259.01 | 7.13 |
| Mar | 260.75 | 254.55 | 274.99 | 7.43 |
| Apr | 265.31 | 253.80 | 273.11 | 7.07 |
| May | 261.41 | 248.79 | 269.83 | 7.80 |
| Jun | 268.37 | 257.10 | 272.88 | 5.78 |
| Jul | 265.93 | 254.57 | 276.72 | 8.00 |
| Aug | 281.93 | 269.70 | 292.39 | 7.76 |
| Sep | 285.49 | 274.70 | 294.28 | 6.66 |
| Oct | 298.88 | 291.76 | 313.94 | 7.06 |
| Nov | 318.96 | 312.93 | 327.67 | 4.50 |
| Dec | 325.21 | 314.29 | 339.78 | 7.50 |
Danaher information and performance
2200 PENNSYLVANIA AVE. N.W., SUITE 800W, WASHINGTON, DC, US
Market capitalization of the Danaher Corp. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of DHR shares in the company outstanding by the market price of one share.
EBITDA of Danaher is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Danaher (DHR) stock dividend
Danaher last paid dividends on 09/27/2024. The next scheduled payment will be on 10/25/2024. The amount of dividends is $1.05 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.
Last Split Date: 01/01/1970
Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.
For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.
Related stocks from Healthcare sector
Commentary
Danaher, known for its conservative guidance, continues to play it safe despite a streak of quarterly earnings beats. While the positive earnings streak boosts confidence, the reluctance of the management to revise forecasts reflects caution. This conservative stance, averaging an influence strength of 8, mirrors uncertainty about future growth rates, potentially leading to short-term stock value fluctuations.
As the company navigates through a bioprocessing downcycle, an improvement in cash flow signals potential for stock buybacks, strengthening its position in the market. With factors like the bioprocessing challenge and China's slow recovery moderately affecting sentiment, the average influence scores 6.8, leading to a more stable outlook in the coming month. Danaher’s sustained fiscal discipline fosters resilience, suggesting that patience might be rewarded as strategic plans unfold. Investors are likely to adopt a watchful stance, given its neutral trend over the period.